[Clinical trial of cefmenoxime in children].
Cefmenoxime (CMX) was intravenously administered to 20 children with the following bacterial infection; pneumonia in 14 cases, purulent meningitis in 2 cases, pyothorax in 2 cases, urinary tract infection in 1 case and brain abscess in 1 case. The daily dosage administered in meningitis, pyothorax and brain abscess ranged from 145-311 mg/kg/day, from 43-88 mg/kg/day in other bacterial infections. The therapeutic efficacy was excellent in 15, good in 3, poor in 2 patients, efficacy rate being 90%. Causative organisms were H. influenzae in 4 cases, S. aureus in 2 cases, Streptococcus sanguis in 1 case, E. coli in 1 case and unknown in 12 cases. All were eliminated with the exception of 2 strains of S. aureus after the administration of CMX. As for side effect, transient eosinophilia was only observed in 1 case.
D000367:Age Factors; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015281:Cefmenoxime; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male
D015281:Cefmenoxime; D002439:Cefotaxime